Back to search results

CPAP Trial for Bronchopulmonary Dysplasia (BPD)

This study, called the CPAP Trial, is looking at whether continuing a breathing support called CPAP (Continuous Positive Airway Pressure) for a longer time can help prevent a lung condition called Bronchopulmonary Dysplasia (BPD) or death in premature babies. Researchers want to see if extending CPAP until 34 weeks after conception, or for at least two extra weeks, is better than gradually switching to a nasal cannula (a small tube that delivers oxygen). This study is for babies born before 29 weeks of pregnancy who are currently on CPAP and meet certain stability requirements. The main goal is to see if there's a difference in BPD or death by 36 weeks after conception. The study aims to enroll 860 babies.

Study design
This is an interventional study comparing two different breathing support strategies. It plans to enroll 860 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed until 36 weeks' postmenstrual age (PMA) to assess for bronchopulmonary dysplasia or death.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07417111

Continued Pressure for Alveolar Protection (CPAP Trial)

Recruiting
NAUp to 31InterventionalPrevention
NICHD Neonatal Research Network
~860 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:CPAPNasal Cannula

At a glance

Recruiting sites
15 of 15 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Bronchopulmonary Dysplasia or Death
Measured over 36 Weeks' PMA

Conditions

Bronchopulmonary Dysplasia (BPD)

Explore related trials

Bronchopulmonary Dysplasia

NCT07417111

Where you'd take part

This study runs at 15 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Case Western Reserve University, Rainbow Babies and Children's Hospital

    Cleveland, Ohiono site contact published

    Recruiting

  • Cincinnati Children's Medical Center

    Cincinnati, Ohiono site contact published

    Recruiting

  • Duke University

    Durham, North Carolinano site contact published

    Recruiting

  • Emory University

    Atlanta, Georgiano site contact published

    Recruiting

  • Northwestern Lurie Children's Hospital of Chicago

    Chicago, Illinoisno site contact published

    Recruiting

  • Sharp Mary Birch Hospital for Women & Newborns

    San Diego, Californiano site contact published

    Recruiting

  • Stanford University

    Palo Alto, Californiano site contact published

    Recruiting

  • University of Alabama at Birmingham

    Birmingham, Alabamano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Colm P. Travers, MD · PRINCIPAL_INVESTIGATOR · University of Alabama at Birmingham

Who to contact

Colm P. Travers, MD
[email protected]
205-934-3100
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Gestational age \<29 weeks at birth
PMA \<32 weeks at study entry
On treatment with CPAP without a rate in FiO2 \<0.25 and PEEP of 4-5 cmH2O
Meet stability criteria:
If previously intubated must be extubated ≥ 72 hours
\<3 self-resolving apneas (≤ 20 s) and/or bradycardia (\<100 bpm) in any hour over previous 6 hours
No episodes of apnea or bradycardia requiring intervention (oxygen/stimulation/bag and mask) for 24 hours
Parents/legal guardians consent for enrollment

Exclusion

Major malformation
Neuromuscular condition that affects respiration
Terminal illness
Decision to withhold or limit support
Too sick to participate in opinion of Attending physician
Clinical shock, sepsis
Planned surgery during study period

What this trial measures

  • Bronchopulmonary Dysplasia or Death36 Weeks' PMA

    The likelihood of BPD or death at 36 weeks' Postmenstrual Age (PMA): a five-level ordinal outcome (death, survival with grade 3 BPD, survival with grade 2 BPD, survival with grade 1 BPD, and survival free of any BPD).